22nd Century Group, Inc.
138 articles about 22nd Century Group, Inc.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
22nd Century Group Appoints James A. Mish to Its Board of DirectorsFurther enhances the Board’s scientific and commercialization experience supporting key market launches
1/21/2022
22nd Century Group, Inc. today announced the appointment of James A. Mish to its Board of Directors (Board).
-
22nd Century Announces $40 Million Common Stock Registered Direct Offering
6/7/2021
22nd Century Group, Inc., a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced that it has entered into a definitive agreement with one institutional investor for the sale of 10 million shares of its common stock at a purchase price of $4.00 per share in a registered direct offering for gross proceeds for $40 million.
-
22nd Century to Participate in May and June 2021 Investor Conferences
5/24/2021
22nd Century Group, Inc., a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced that the Company will participate in the following virtual investor conferences in May and June 2021
-
22nd Century Group Installs State-of-the-Art Nicotine Testing Equipment to Enhance VLN® Production
5/5/2021
Investment in New Lab Capabilities Will Reduce Testing Costs by 90% and Improve Turnaround Time from Weeks to Hours
-
22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles “Still on the Table”
4/30/2021
Applauds Decisive Move and Commitment by FDA to Advance Rule Banning Menthol As First Step to Reduce Addiction, Improve Quitting, Reduce Youth Initiation and Reduced Disparities; Movement on Nicotine Cap by FDA Expected to be Forthcoming
-
22nd Century Delivers 3.6 Million Variable Nicotine Content Research Cigarettes for Independent Scientific Studies
4/26/2021
To Date, 22nd Century Has Provided More Than 31 Million Variable Nicotine Content Research Cigarettes for Numerous Independent Scientific Studies
-
22nd Century Fully Prepared to Deliver the Solution as Biden Administration Considers Requirement to Lower Nicotine Level for All Cigarettes Sold in U.S.
4/20/2021
22nd Century Group, Inc., a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very-low nicotine content tobacco, and hemp/cannabis research, reports that it is fully prepared to partner with the U.S. Food and Drug Administration to launch its VLN® reduced nicotine content cigarette brand and license its reduced nicotine content tobacco technology to every cigarette manufacturer.
-
22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants
3/12/2021
22nd Century Group, Inc., a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced that it has received an additional $3.7 million, for total net proceeds of $11.8 million, from the completion of the cash exercise of warrants during February and March of 2021.
-
22nd Century Group to Present at 13th Annual LD Micro Main Event Conference
12/4/2020
22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it will be presenting at the 13 th Annual LD Micro Main Event Conference on Monday, December 14, 2020, at 9:20 a.m. ET. James A. Mish, chief executive officer of 22nd Century Group, will be presenting to a live, virtual
-
22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020
8/6/2020
Key Highlights: Net sales revenue increased approximately 11% to $6.4 million Gross profit continues to show improvement year-over-year as a result of targeted actions to improve margins and cost structure Operating loss improved by approximately $276 thousand Adjusted EBITDA improved 21% Appointed new CEO, James A. Mish and new CFO, John Franzino WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a
-
BioSpace Movers & Shakers, June 5
6/5/2020
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers. -
22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer
6/3/2020
Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related consumer products
-
22nd Century Group Reports First Quarter 2020 Financial Results
5/7/2020
22nd Century Group, Inc., a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, reported results for the first quarter ended March 31, 2020.
-
22nd Century Group Completes Successful Non-GMO Very Low Nicotine Content Tobacco Research Field Trials
4/30/2020
Research Validates New Non-GMO Methodologies for Reducing Nicotine in Tobacco Plants by up to 99%
-
22nd Century Group, Inc. Files 2019 Annual Report
3/12/2020
Maintains Strong Balance Sheet; Momentum Continues for Modified Risk Tobacco Product and Major Milestone Achieved in Hemp/Cannabis Research
-
22nd Century Group Adds to Leadership TeamNew Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement
3/10/2020
22nd Century Group, Inc. announced the appointment of Lisa Parks as its Vice President of Acquisitions and Mei Kuo as its new Director of Communications and Investor Relations.
-
22nd Century Group Files 2019 Third Quarter Report
11/7/2019
22nd Century Builds Strong Momentum for its Very Low Nicotine Content Tobacco and Makes Significant Progress in the Development of Valuable New Hemp/Cannabis Plants
-
22nd Century Group Files 2019 Second Quarter Report
8/7/2019
22nd Century Group, Inc., a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco and hemp/cannabis research, announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 with the U.S. Securities and Exchange Commission.
-
22nd Century Group Appoints Cliff Fleet Chief Executive Officer
8/5/2019
Mr. Fleet has also been elected to serve as a member of the Company’s Board of Directors.